
Joyzyme Group Limited
8622.HKHKSEHealthcareDrug Manufacturers - Specialty & Generic
最新数据
HK$0.164
+HK$0.001 · +0.61%
8622.HK公司概览
历史价格可能经过调整并有所延迟。
公司概况
公司网站Huakang Biomedical Holdings Company Limited operates as an investment holding firm, primarily dedicated to the research, development, manufacturing, marketing, and distribution of in-vitro diagnostic (IVD) reagents within the People's Republic of China. Its comprehensive product portfolio encompasses IVD reagents designed for assessing male and female fertility, detecting parasite antibodies, and identifying the Epstein-Barr virus. Additionally, the company provides auxiliary reproductive supplies and equipment, alongside a range of healthcare products and nutritional supplements marketed under its 'Nutronic' brand, which are sold through both digital and physical platforms. Products are distributed directly to hospitals and medical institutions, as well as through a network of third-party distributors. The company was founded in 1992 and maintains its headquarters in Wan Chai, Hong Kong.
- 行业
- Drug Manufacturers - Specialty & Generic
- 部门
- Healthcare
- 总部
- HK
- 首席执行官
- Chunguang Zhang
- 上市以来
- 2018年12月13日
- 雇员
- 101
市场位置
- 成交量
- 11.2万
- 0.47× 平均值
- 平均成交量
- 24.04万
- 日均成交量
- 市值
- 8505.29万 HKD
- 贝塔
- 0.72
- 市场参考 1
财务数据
财务快照
最近十二个月估值与收益率
- 企业价值
- 1.64亿 CNY
- EV/EBITDA
- -26.57×
- 盈利收益率
- -2.56%
- 自由现金流收益率
- -1.68%
盈利能力和效率
- 净资产收益率
- -9.79%
- 资产收益率
- -7.51%
- 投入资本回报率
- -13.91%
财务健康
- 流动比率
- 3.88×
- 奥特曼 Z 分数
- 3.26
- 皮奥特罗斯基 F 分数
- 2 共 9 个
财报历史与展望
- 最新财年每股收益
- -0.01
- 2025财年
- 最新财年收入
- 2828.2万 CNY
- 2025财年 · 同比+11.53%
年度每股收益趋势
已公布业绩及可用的市场共识预期。
年度营收趋势
已公布业绩及可用的市场共识预期。
8622.HK同业公司
继续GoAI的研究
在 GoAI 中研究8622.HKresearch.disclaimer





